

Japan reveals adverse events following COVID-19 vaccination in youngsters

11 August 2021 | News

The adverse events of the coronavirus vaccine in elderly people have been studied; however, those of the coronavirus vaccine in young people have not been studied in Japan



A cross-sectional study was recently conducted to clarify the adverse events of COVID-19 vaccines in Japanese young population.

Currently, in Japan, the COMIRNATY (Pfizer) intramuscular injection is used for priority vaccinations, and COVID-19 Vaccine Moderna Intramuscular Injection is used for vaccination in workplaces.

The study population included people who had a first time vaccination using COVID-19 Vaccine Moderna Intramuscular Injection.

The researchers analyzed 1,877 data obtained from a questionnaire survey of 1,993 vaccinated individuals. Eighty-two percent of participants complained of local adverse events such as headache, fatigue, nausea. Injection site pain was the most common local adverse event (71%). Systemic adverse events occurred in 48% of participants. The most common adverse event was myalgia or muscle pain (34%).

The results of this study clarified for the first time that age less than 20 years is a risk factor for systemic adverse events from the COVID-19 Vaccine Moderna Intramuscular Injection.

This information will give impacts on considering adverse events and its mechanisms in mRNA vaccination.